Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.20.1
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Commitments and Contingencies (Textual)      
Rent expense for space $ 13,080    
Rent expense   $ 350,979 $ 298,972
2011 Exclusive Agreement [Member]      
Commitments and Contingencies (Textual)      
Milestone payment   $ 765,000  
License reduced percentage   50.00%  
Aggregate maintenance fees   $ 80,000  
Maintenance fees annually   $ 50,000  
Royalty percentage   2.00%  
Minimum royalty expense   $ 75,000  
Royalty description   The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).  
2013 Exclusive Agreement [Member]      
Commitments and Contingencies (Textual)      
Milestone payment   $ 765,000  
License reduced percentage   50.00%  
Aggregate maintenance fees   $ 7,500  
Maintenance fees annually   $ 5,000  
Royalty percentage   2.00%  
Minimum royalty expense   $ 75,000  
Royalty description   The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).  
License costs   $ 10,000